OKYO Pharma to Participate in 2026 Jefferies Global Healthcare Conference in London

Summary by AI BETAClose X

OKYO Pharma will participate in the Jefferies Global Healthcare Conference in London November 16–19, 2026 with leadership available for one-on-one investor meetings; the company reported that lead candidate urcosimod has enrolled first patients in the Phase 3 NEPTUNE trial, an operational milestone that could materially de-risk the program, and the announcement disclosed no revenue, profit/loss, cash, debt or guidance figures.

Disclaimer*

UK 100

Latest directors dealings